UCB’s Fintepla® (fenfluramine) has obtained an expanded indication to treat seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients at least two years of age.

• When first FDA approved in 2020, Fintepla was indicated only to treat seizures associated with Dravet Both Dravet syndrome and Lennox-Gastaut syndrome are rare conditions that cause severe, drug-resistant epilepsy.
• Recommended Fintepla dosing is based on the patient’s diagnosis, weight, and renal health; treatment efficacy and tolerability; and whether the patient is taking stiripentol and clobazam.